Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07184619
PHASE3

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

Sponsor: Newron Pharmaceuticals SPA

View on ClinicalTrials.gov

Summary

This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in patients with documented treatment-resistant schizophrenia (TRS) who have prospectively demonstrated inadequate response to their current stable therapeutic dose of an antipsychotic(s). Approximately 400 patients will be randomized equally (1:1) to each of the two treatment groups in this study.

Official title: A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

400

Start Date

2026-01-23

Completion Date

2026-09-01

Last Updated

2026-04-03

Healthy Volunteers

No

Interventions

DRUG

Evenamide 15 mg bid

Evenamide capsules 15 mg bid for a total of 12 weeks of add-on treatment

DRUG

Placebo

Matching placebo capsules bid for a total of 12 weeks of add-on treatment

Locations (5)

UCLA DGSOM, UCLA Health, UCLA Semel Institute

Los Angeles, California, United States

University of Miami, Miller School of Medicine; Jackson Behavioral Health Hospital

Miami, Florida, United States

Grady Behavioral Health Center, -Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine

Atlanta, Georgia, United States

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine

Baltimore, Maryland, United States

Manhattan Psychiatric Center, The Nathan Kline Institute for Psychiatric Research

New York, New York, United States